Home For Health Plans

For Health Plans

Leva is a clinically proven, at home prescription-required treatment option for female urinary incontinence, a serious medical condition that affects over 60% of your female members.1

How Leva Works

The Leva Pelvic Health System combines motion-based, multi-sensor technology embedded in a flexible intra-vaginal probe with integrated software to provide Supervised Pelvic Floor Muscle Therapy (PFMT) for the treatment of female pelvic floor disorders.

Leva Device with Motion Sensors + Software Technology

Inserted vaginally, the Leva device uses motion sensors to detect movement during pelvic floor muscle training and communicates in real-time with the software to direct treatment.

leva device app on a mobile device

Leva Women’s Center

The Leva system is supported by the Leva Women’s Center, a team of coaches who help patients with training, adherence and personal symptom goals.

Woman wearing a headset

Patient Report

The patient report captures the adherence and symptom data that providers need to monitor patient progress over their 12-week Leva treatment program.

report on a clipboard

UI Indication

The Leva Pelvic Health System is an FDA-cleared, prescription-only medical device indicated for the treatment of stress, mixed and mild to moderate urgency urinary incontinence (including overactive bladder) in women. The Leva Pelvic Health System is a Class II medical device and was authorized by the FDA through a 510(k) Pre-Market filing (K213913). The Leva Pelvic Health System also received Breakthrough Device Designation (Q211109) from the FDA on October 28, 2021, for the chronic fecal incontinence indication.

Pharmacy Code

60002099440

HCPCS CODE

S9002

Clinical Outcomes

Pivotal Data

Published in Obstetrics & Gynecology (“The Green Journal”), our pivotal 8-week randomized controlled trial (RCT) with 299 women demonstrates that pelvic floor muscle training guided by Leva delivers better UI symptom improvement than an at home program alone.2 Primary outcomes were change in stress urinary incontinence (SUI) episodes on a 3-day bladder diary and change in Urogenital Distress Inventory (UDI-6) score.

  • The 3-day bladder diary results showed that the median number of SUI episodes at 8 weeks was significantly fewer in the Leva arm than in the Control arm. Most Leva users saw an 80% reduction in leakage episodes.2
  • For the (UDI-6) scores on symptom relief, the Leva users reached a significantly greater score improvement compared to the Control arm. 
  • The Leva users saw statistically significant symptom improvement as early as 4 weeks into treatment.2

Read the full study, published in ACOG’s Green Journal in April 2022, here

Long Term Data

Published in the International Urogynecology Journal, an 18- & 24-month long term follow-up to the 8-week pivotal, followed the same 299 participants and UI symptom improvement persisted for two years, despite Leva users no longer using Leva. Findings show durable results lasting for two years. Leva is a scalable option for practices to implement for first line UI care.

Read the full study, published in the International Urogynecology Journal in January 2024, here

Real World User Evidence

Our peer-reviewed real-world evidence study of 947 Leva users, published in JMIR Publications in June 2024, found:

  • Leva is effective for stress, mixed and urgency urinary incontinence (including overactive bladder).
  • 74% of Leva users see significant UI symptom relief.

Read the full study, published in JMIR Publications in June 2024, here

Budget Impact Model Study

A peer-reviewed study in the Journal of Medical Economics shows that using the FDA-cleared Leva Pelvic Health System as a first-line treatment for female urinary incontinence can significantly reduce health plan costs. Key results from the analysis include:

  • In a United States commercial health plan with 1 million members, 334,191 were adult women, of whom 31,438 (9.4%) were treated for UI over 24 months. The study compared health-plan costs for two groups: a group receiving current clinical practice for first-line UI care (CCP) and a group in which 15% of patients received Leva, while all others received CCP.5
  • The total estimated 24-month cost per treated patient was $10,447 for the group in which 15% received Leva versus $11,267 for the 85% receiving CCP. The total cost for the Leva group ($10,447) includes the intervention cost of $2,100.
  • This resulted in total projected savings for the 1-million-member health plan of > $25.7 million over 24 months, or $1.07 PMPM.

Read the full study, published in the Journal of Medical Economics in May 2025 here

Leva Pelvic Health System Overview and Clinical Evidence Summary

Discover how the FDA-cleared Leva Pelvic Health System is transforming urinary incontinence therapy. Explore our clinical evidence, market adoption, and provider utilization in this comprehensive overview.

Read the overview and summary here

Plan Savings With Leva

Publications

Several publications support the finding that UI is costly and undertreated, and there is a real lack of documented first line care.

Conclusion: Women with SUI/MUI consume significantly higher medical resources and incur higher costs to health plans, compared to women without SUI/MUI. While reasons for this are not fully understood, improved and standardized treatment for women with SUI/MUI may positively affect cost and outcomes.

Status: Published; Neurourol Urodyn. 2022; 1-10. doi:10.1002/nau.24989

Conclusion: Majority of SUI or MUI patients do not receive a behavioral intervention as their first-line treatment, which is a recommendation by professional society guidelines. This was found to affect the cost burden for health plans; those that were non-adherent had significantly higher costs 2-years post-index.

Status: Accepted; Neurourol Urodyn – publication date TBD

Conclusion: Percentage of women with a PT visit associated with an incident SUI or MUI diagnosis was low (2.6%), and 30% of this group completed three or more PT visits. This suggests poor adherence to clinical guidelines regarding supervised treatment of UI in women.4

Status: Published; Neurourol Urodyn. 2022; 1-8. doi:10.1002/nau.24913

Data on file: Economic Budget Impact Model- Savings opportunity through offering improved first-line care for members with Leva vs. historic standard of care (SOC)* Majority of savings through decreased utilization of advanced treatments.

*PFMT supervised by a PT or unsupervised Kegels

Interested In Learning More About Urinary Incontinence?

  1. Patel UJ, Godecker AL, Giles DL, Brown HW. Updated Prevalence of Urinary Incontinence in Women: 2015-2018 National Population-Based Survey Data [published online ahead of print, 2022 Jan 12]. Female Pelvic Med Reconstr Surg. 2022;10.1097/SPV.0000000000001127. doi:10.1097/SPV.0000000000001127
  2. Weinstein, MM, Dunivan, G, Guaderrama, NM, Richter, HE. Digital Therapeutic Device for Urinary Incontinence: A Randomized Controlled Trial [published online ahead of print, 2022 March 10]. Obstet Gynecol. doi: 10.1097/AOG.0000000000004725.
  3. Sanderson DJ, Zavez A, Meekins AR, Eddib A, Lee TG, Barber MD, Duecy E. The Patient Acceptable Symptom State in Female Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 Jan 1;28(1):33-39. doi: 10.1097/SPV.0000000000001055. PMID: 34009829.
  4. McKinney, JL, Datar, M, Pan, L-C, Goss, T, Keyser, LE, Pulliam, SJ. Retrospective claims analysis of physical therapy utilization among women with stress or mixed urinary incontinence. Neurourol Urodyn. 2022; 1- 8. doi:10.1002/nau.24913
  5. Hall, E., Sharma, A., Goss, T. F., & Hung, K. (2025). U.S. payer budget impact of the Leva Pelvic Health System to improve pelvic floor muscle training as first-line treatment of female urinary incontinence compared to real-world clinical practice. Journal of Medical Economics, 28(1), 637–647. https://doi.org/10.1080/13696998.2025.2494940